Complete Response to PD-L1 Targeted Treatment in a Patient with Anaplastic Papillary Tumor of the Pineal Region

Flechl B, Ackerl M, Aysegül Ilhan-Mutlu, Woehrer A, Hainfellner J, Preusser M, Widhalm G, Kiesel B, Lütgendorf-Caucig C, Dieckmann K and Marosi C

Department of Medicine, Medical University of Vienna, Austria
Department of Medicine, Institute of Radiation Oncology, Austria
Department of Medicine, MedAustron Ion Therapy Center, Austria
Department of Medicine, Medical University of Vienna, Austria
Department of Neurosurgery, Medical University of Vienna, Austria
Department of Radiation Oncology, Medical University of Vienna, Austria

^*Correspondance to: Marosi C 

 PDF  Full Text Case Report | Open Access

Abstract:

An adult female patient underwent repeated neurosurgical procedures, radiosurgery, radiation therapy and chemotherapy for a recurrent and metastatic anaplastic papillary tumor of the pineal region. For a radiographically assured new relapse, she was treated with the anti-death receptor one antibody pembrolizumab given infused at a dose of 2mg/kg every two weeks. Within a year, the tumor manifestations of the patient shrank continuously and she achieved complete remission which remained stable since now more than a year. The therapy was discontinued after eighteen months. The report of efficacy of cancer immune therapy in an advanced patient shows a treatment opportunity in this orphan disease.

Keywords:

Cite the Article:

Flechl B, Ackerl M, Ilhan-Mutlu A, Woehrer A, Hainfellner J, Preusser M, et al. Complete Response to PD-L1 Targeted Treatment in a Patient with Anaplastic Papillary Tumor of the Pineal Region. Ann Clin Case Rep. 2017; 2: 1451.